➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
Moodys
Colorcon
Mallinckrodt
Boehringer Ingelheim

Last Updated: September 25, 2020

DrugPatentWatch Database Preview

Litigation Details for Finjan, Inc. v. Qualys Inc. (N.D. Cal. 2018)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Finjan, Inc. v. Qualys Inc. (N.D. Cal. 2018)

Docket   Start Trial Date Filed 2018-11-29
Court District Court, N.D. California Date Terminated
Cause 35:271 Patent Infringement Assigned To Yvonne Gonzalez Rogers
Jury Demand Both Referred To
Parties FINJAN, INC.; QUALYS INC.
Patents 10,154,990; 10,183,968; 10,183,975; 10,231,964; 10,231,975; 10,231,983; 10,239,954; 10,246,708; 10,266,822; 10,278,974; 10,327,926; 10,331,349; 10,335,388; 10,335,390; 10,335,391; 10,335,397; 10,335,420; 10,335,494; 10,363,320; 10,369,409; 10,370,414; 10,375,964; 10,377,731; 10,379,975; 10,383,344; 10,383,357; 10,383,954; 10,385,399; 10,386,359; 10,386,366; 10,386,376; 10,391,154; 10,392,349; 10,392,357; 10,392,406; 10,392,413; 10,401,371; 10,406,332; 10,406,383; 10,407,393; 10,421,954; 10,494,413; 10,494,414; 10,633,423; 6,183,974; 6,335,369; 6,355,415; 6,355,425; 6,387,383; 6,406,387; 6,406,731; 6,420,322; 6,423,319; 6,613,357; 6,844,390; 6,893,253; 6,893,633; 6,893,639; 6,919,341; 6,919,348; 6,919,392; 6,923,968; 6,962,151; 6,974,893; 7,270,968; 7,305,986; 7,320,968; 7,338,968; 7,348,319; 7,354,416; 7,358,393; 7,358,402; 7,361,650; 7,364,752; 7,371,408; 7,371,409; 7,377,866; 7,378,418; 7,378,423; 7,384,354; 7,384,650; 7,392,398; 7,392,844; 7,396,341; 7,396,822; 7,416,752; 7,422,388; 7,423,391; 7,425,326; 7,425,333; 7,494,815; 7,520,866; 7,731,986; 7,772,462; 7,893,287; 7,919,322; 7,964,183; 7,964,219; 7,964,357; 7,964,359; 7,964,402; 7,964,647; 7,968,263; 7,968,302; 7,968,351; 7,968,735; 8,008,006; 8,008,032; 8,236,975; 8,277,822; 8,323,677; 8,327,844; 8,329,419; 8,329,752; 8,333,974; 8,334,413; 8,338,376; 8,338,385; 8,338,395; 8,338,408; 8,349,321; 8,354,409; 8,357,369; 8,357,375; 8,357,394; 8,357,677; 8,367,402; 8,367,415; 8,372,396; 8,372,968; 8,377,919; 8,383,359; 8,383,417; 8,387,351; 8,388,954; 8,394,367; 8,394,372; 8,394,377; 8,394,387; 8,394,405; 8,394,406; 8,394,407; 8,399,396; 8,415,337; 8,415,345; 8,415,348; 8,415,355; 8,415,363; 8,415,382; 8,415,393; 8,415,396; 8,420,650; 8,425,353; 8,591,983; 8,613,965; 8,647,639; 8,752,419; 8,822,407; 8,822,423; 8,926,493; 8,962,593; 8,962,630; 8,962,804; 8,975,382; 8,980,885; 9,227,983; 9,265,893; 9,271,866; 9,271,968; 9,285,364; 9,285,372; 9,326,974; 9,334,320; 9,345,677; 9,351,975; 9,353,366; 9,353,368; 9,353,371; 9,358,338; 9,359,367; 9,363,752; 9,371,377; 9,371,392; 9,371,393; 9,375,412; 9,375,494; 9,376,366; 9,381,305; 9,381,416; 9,382,321; 9,383,349; 9,383,370; 9,386,990; 9,387,360; 9,387,383; 9,388,425; 9,393,305; 9,393,351; 9,393,372; 9,394,344; 9,395,364; 9,402,919; 9,408,393; 9,408,893; 9,410,954; 9,416,366; 9,416,367; 9,416,371; 9,421,351; 9,422,335; 9,630,930; 9,650,393; 9,650,395; 9,650,416; 9,708,397; 9,822,351; 9,879,267; 9,974,302; 9,974,839; 9,975,919; 9,983,185
Attorneys Christopher Don Mays; Edward G. Poplawski; James R. Hannah; Lisa Kobialka; Olivia M Kim; Paul J. Andre; Ryan R. Smith
Firms Kramer Levin Naftalis & Frankel LLP; Wilson Sonsini Goodrich & Rosati; Wilson Sonsini Goodrich & Rosati, P.C.; Wilson Sonsini Goodrich and Rosati
Link to Docket External link to docket
Biologic Drugs cited in Finjan, Inc. v. Qualys Inc.

The biologic drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for Finjan, Inc. v. Qualys Inc. (N.D. Cal. 2018)

Date Filed Document No. Description Snippet Link To Document
2020-03-14 50 Opposition/Response to Motion ,975,305 (“’305 Patent”) to allege that Finjan should be precluded 8 from asserting different claims…on Finjan’s patent license to Trend Micro (the “Agreement”). 7 Under the Agreement, 8 9 10 11…motion for leave to assert patent exhaustion and implied 7 license defenses. 8 2. …Martin Corp. v. Network Sols., Inc., 194 F.3d 980 (9th Cir. 1999) .................................…Martin Corp. v. Network 15 Sols., Inc., 194 F.3d 980, 986 (9th Cir. 1999). 16 Qualys alleges External link to document
2020-03-16 52 Response ( Non Motion ) requests content. See Dkt. 42-5 ‘968 patent at Fig. 2; 8:8-32. Thus, whether the Court’s ultimate … five of the seven patents-in-suit: U.S. Patent Nos. 6,154,844 (“the ’844 patent”); 6,965,968 (“the … 23 ’968 patent); 8,141,154 (“the ’154 patent”); 7,418,731 (“the ’731 patent”); and 6,154,844 (“the…III. ’408 PATENT 13 A. ’408 Patent Overview 14 The ’408 patent describes a… ’968 PATENT 19 A. ’968 Patent Overview 20 The ’968 patent is generally External link to document
2020-04-13 60 Exhibit F 90071 Telephone: (323) 210-2901 6 Facsimile: (866) 974-7329 7 RYAN R. SMITH (SBN 229323… a processor that ‘154 Patent: Abstract; Claims 1, 6; Figs. 1-5; 2:64-67; 3:1-67; 4:15-26… 6 QUALYS’S PATENT L.R. 4-2 DISCLOSURES … ’408 Patent: Abstract; Claims 1, 8, 9, 22; Figs. 1, 2, 5, 6, 7; 1:59-2:65; 3:22-45;… ’154 Patent: Figs. 2-5; 6:60-65, 8:54-60, 15:26-29; claims 1-3 External link to document
2020-04-14 61 Order on Motion to Amend/Correct 21 Patent”), 8,225,408 (the “’408 Patent”),6,965,968 (the “’968 Patent”), 7,418,731 (the…action.” Trevino v. Gates, 99 F.3d 911, 923 (9th Cir. 1996). A patent 16… 20 Patent Nos. 6,154,844 (the “’844 Patent”), 8,677,494 (the “’494 Patent”), 7,975,305 (the…) for direct and indirect infringement of six of its patents. (Dkt. No. 1 …asserting claims 3-4, 6-12, and 14-25 of the ’305 4 Patent), with Reexamination External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
AstraZeneca
Johnson and Johnson
Colorcon
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.